Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.63%, the Hang Seng Tech Index down by 0.67%, and the Hang Seng China Enterprises Index decreasing by 0.88% [1] - In contrast, the innovative drug sector saw significant gains, with the Hang Seng Biotechnology Index rising by 2.97% [1] Company Performance - Xiaomi Group's stock dropped over 3%, with a maximum intraday decline exceeding 5% [2][3] - Innovative drug stocks performed well, with Huahao Zhongtian Pharmaceutical surging over 55%, Kangfang Biotech increasing by 14.33%, and other companies like Basestone Pharmaceuticals and Innovent Biologics also showing positive growth [6] IPO Activity - Luxshare Precision announced plans to issue H shares and list on the Hong Kong Stock Exchange [7] - Lens Technology has initiated its IPO process, planning to officially list on July 9 [8] - GoerTek intends to spin off its microelectronics subsidiary for an IPO in Hong Kong [9] - These companies are recognized as the "three giants of the fruit chain," and the China Securities Regulatory Commission has expressed support for leading domestic enterprises to list in Hong Kong [10] Regulatory Developments - The Hong Kong Stock Exchange launched an Integrated Fund Platform (IFP) order transmission service to enhance market efficiency [11] - The service aims to connect key participants in the fund distribution ecosystem and will welcome 33 companies as initial participants [12]
创新药概念股逆市大涨
中国基金报·2025-07-03 11:20